The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Abstract
PURPOSE: To determine, in women with primary operable breast cancer, if preoperative doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan; AC) therapy yields a better outcome than postoperative AC therapy, if a relationship exists between outcome and tumor response to preoperative chemotherapy, and if such therapy results in the performance of more lumpectomies. PATIENTS AND METHODS: Women (1,523) enrolled onto National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 were randomly assigned to preoperative or postoperative AC therapy. Clinical tumor response to preoperative therapy was graded as complete (cCR), partial (cPR), or no response (cNR). Tumors with a cCR were further categorized as either pathologic complete response (pCR) or invasive cells (pINV). Disease-free survival (DFS), distant disease-free survival (DDFS), and survival were estimated through 5 years and compared between treatment groups. In the preoperative arm, proportional-hazards models were used to investigate the relationship between outcome and tumor response. RESULTS: There was no significant difference in DFS, DDFS, or survival (P = .99, .70, and .83, respectively) among patients in either group. More patients treated preoperatively than postoperatively underwent lumpectomy and radiation therapy (67.8% v 59.8%, respectively). Rates of ipsilateral breast tumor recurrence (IBTR) after lumpectomy were similar in both groups (7.9% and 5.8%, respectively; P = .23). Outcome was better in women whose tumors showed a pCR than in those with a pINV, cPR, or cNR (relapse-free survival [RFS] rates, 85.7%, 76.9%, 68.1%, and 63.9%, respectively; P < .0001), even when baseline prognostic variables were controlled. When prognostic models were compared for each treatment group, the preoperative model, which included breast tumor response as a variable, discriminated outcome among patients to about the same degree as the postoperative model. CONCLUSION: Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certain patients with stages I and II disease, and can be used to study breast cancer biology. Tumor response to preoperative chemotherapy correlates with outcome and could be a surrogate for evaluating the effect of chemotherapy on micrometastases; however, knowledge of such a response provided little prognostic information beyond that which resulted from postoperative therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,801
Self-citationFisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Self-citationDQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,327
Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
Fisher, B., Dignam, J., Emir, B., Bryant, J., DeCillis, A., Wolmark, N., Wickerham, D. L., Dimitrov, N. V., Abramson, N., Atkins, J. N., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.22.1673 · Cited by 521
Self-citationScholl, S. M., Fourquet, A., Asselain, B., Pierga, J. Y., Vilcoq, J. R., Durand, J. C., Dorval, T., Palangié, T., Jouve, M., Beuzeboc, P., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90537-1 · Cited by 424
Fisher, B., Gündüz, N., & Saffer, E. (1983) · PubMed · Cited by 422
Self-citationEffect of surgical removal on the growth and kinetics of residual tumor.
Gündüz, N., Fisher, B., & Saffer, E. (1979) · PubMed · Cited by 410
Self-citationPresence of a growth-stimulating factor in serum following primary tumor removal in mice.
Fisher, B., Gündüz, N., Coyle, J., Rudock, C., & Saffer, E. (1989) · PubMed · Cited by 361
Self-citationMauriac, L., Durand, M., Avril, A., & Dilhuydy, J.-M. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057953 · Cited by 268
Kinetics of mammary tumor cell growth and implications for therapy
Skipper, H. E. (1971) · Cancer · doi:10.1002/1097-0142(197112)28:6<1479::aid-cncr2820280622>3.0.co;2-m · Cited by 234
Scholl, S., Pierga, J., Asselain, B. J. R., Beuzeboc, P., Dorval, T., García-Giralt, E., Jouve, M., Palangié, T., Remvikos, Y., Durand, J. C., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00454-8 · Cited by 152
Fisher, B., Saffer, E., Rudock, C., et al. (1989) · PubMed · Cited by 139
Self-citationFisher, B., Wolmark, N., Fisher, E. R., & Deutsch, M. (1985) · World Journal of Surgery · doi:10.1007/bf01655182 · Cited by 70
Self-citationPreoperative chemotherapy followed by mastectomy for locally advanced breast cancer
Schick, P. M., Goodstein, J., Moor, J., Butler, J., & Senter, K. L. (1983) · Journal of Surgical Oncology · doi:10.1002/jso.2930220415 · Cited by 60
Sorace, R. A., Bagley, C. S., Lichter, A. S., Danforth, D. N., Wesley, M. W., Young, R. C., & Lippman, M. E. (1985) · World Journal of Surgery · doi:10.1007/bf01655193 · Cited by 46
Preoperative Chemotherapy in Operable Breast Cancer
van de Velde, C. J. �. (1993) · Drugs · doi:10.2165/00003495-199300452-00006 · Cited by 9
Cited by
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
“Preoperative therapy, initially used only for locally advanced breast cancer, has become more common for patients with operable disease.(1-17) This allows more individuals to undergo breast-conserving procedures and provides for observation of response to treatment.”
BackgroundMethodResultInfluentialSelf-citation
Metadata
- Authors
- Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., Margolese, R. G., Cruz, A. B., Hoehn, J. L., Lees, A. W., Dimitrov, N. V., & Bear, H. D.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-08
- Volume
- 16
- Issue
- 8
- Pages
- 2672-2685
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139510434
- Cited by
- 2,165
- References
- 16
- FWCI
- 19.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.